Investigating the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents
NCT ID: NCT03470688
Last Updated: 2018-03-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
5000 participants
OBSERVATIONAL
2018-03-01
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Participants With Rheumatoid Arthritis (RA) Who Are Treated With Abatacept or Tumor Necrosis Factor Inhibitors in Australia
NCT03663829
Observational Study of Tocilizumab in Participants With Rheumatoid Arthritis in Australia
NCT01683604
Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy
NCT00124982
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
NCT07137598
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics
NCT01636817
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Originator
Originator anti-TNF agents. Dosage as per physician's decision based on approved indication.
Originator
Originator anti-TNF agents
Biosimilar
Biosimilar anti-TNF agents. Dosage as per physician's decision based on approved indication.
Biosimilar
Biosimilar anti-TNF agents
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Originator
Originator anti-TNF agents
Biosimilar
Biosimilar anti-TNF agents
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Opal Rheumatology Ltd.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paul Bird
Role: PRINCIPAL_INVESTIGATOR
Optimus Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Canberra Rheumatology
Canberra, Australian Capital Territory, Australia
Rheumatology ACT
Canberra, Australian Capital Territory, Australia
Susan Street Specialists Centre
Camperdown, New South Wales, Australia
Hills Rheumatology
Castle Hill, New South Wales, Australia
Orthopaedic and Arthritis Centre
Chatswood, New South Wales, Australia
Georgetown Arthritis
Georgetown, New South Wales, Australia
Combined Rheumatology Practice
Kogarah, New South Wales, Australia
Rheumatology United
Penrith, New South Wales, Australia
Coast Joint Care
Maroochydore, Queensland, Australia
Gold Coast Rheumatology
Southport, Queensland, Australia
Townsville Hospital - Rheumatology
Townsville, Queensland, Australia
Hobart Specialists Group
Hobart, Tasmania, Australia
Rheumatology Tasmania
Hobart, Tasmania, Australia
Southern Rheumatology
Brighton, Victoria, Australia
Northern Rheumatology and Specialists
Brunswick, Victoria, Australia
Monash Rheumatology
Clayton, Victoria, Australia
Coburg Rheumatology
Coburg, Victoria, Australia
Melbourne Arthritis Associates
Fitzroy, Victoria, Australia
Footscray Specialist Rooms
Footscray, Victoria, Australia
Barwon Rheumatology Service
Geelong, Victoria, Australia
Peninsula Rheumatology
Langwarrin, Victoria, Australia
Subiaco Rheumatology
Subiaco, Western Australia, Australia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MSD biosimilars
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.